Endovascular treatment or general treatment: how should acute ischemic stroke patients choose to benefit from them the most? 

A systematic review and meta-analysis

Weinan Yang, MBa, Lincheng Zhang, MBa, Qigu Yao, MBa, Weiyan Chen, PhDb, Weiji Yang, MSc, Suqing Zhang, MBa, Lan He, MBa, Hong Li, PhDc, Yuyan Zhang, PhDc, * Suqing Zhang, MBa, Lan He, MBa, Hong Li, PhDc, Yuyan Zhang, PhDc, * * Suqing Zhang, MBd, Lan He, MBa, Hong Li, PhDe, Yuyan Zhang, PhDe, Weinan Yang, MBa

Abstract

Background: Acute ischemic stroke due to large-vessel occlusion is a leading cause of death and disability, and therapeutic time window was limited to 4.5 hours when treated with intravenous thrombolysis. It has been acknowledged that endovascular treatment (EVT) is superior to general treatment (only medication, including intravenous recombinant tissue plasminogen activator (rt-PA)) in improving the outcome of AIS since 2015. However, the benefits were limited to improvement of functional outcomes and functional independence. Hence, this meta-analysis was conducted to summarize the benefits of EVT for acute ischemic stroke, explore underlying indications of EVT for AIS patients and suggest implications for clinical practice and future research.

Methods: A search was performed to identify eligible studies in PubMed, Scopus and Web of Science updated to February 5, 2019. Functional outcomes, the modified Rankin Scale (mRS) 0–1, mRS 0–2, all-cause mortality, symptomatic intracerebral hemorrhage and asymptomatic intracerebral hemorrhage (aICH) at 90 days were selected as outcomes. Data was pooled to calculate the odds ratio (OR) and 95% confidence interval (CI). Heterogeneity, subgroup analysis, sensitivity analysis and publication bias were also performed in this meta-analysis.

Results: Eighteen studies comprising 3831 patients were included and analyzed in this meta-analysis. In comparison with general treatment, improved functional outcomes (mRS 0–1: OR = 1.68, 95% CI = 1.43–1.97, inconsistency index [I²] = 57%, P < .00001; mRS 0–2: OR = 1.78, 95% CI = 1.55–2.03, I² = 69%, P < .00001), reduced risk of all-cause mortality (OR = 0.82, 95% CI = 0.70–0.98, I² = 27%, P = .03) but higher risk of aICH (OR = 1.43, 95% CI = 1.05–1.95, I² = 0%, P = .02) at 90 days were found in AIS patients treated with EVT. Age < 70, National Institutes of Health Stroke Scale ≥ 20 and maximum delay for invention > 5 hours could improve clinical outcomes following EVT. In sensitivity analysis, it showed that 2 studies had a great influence on the pooled ORs. No potential publication bias was found in this meta-analysis.

Conclusion: Taken together, EVT, which led to improved functional outcomes and decreased risk of death, is superior to general treatment for AIS patients with age < 70, National Institutes of Health Stroke Scale ≥ 20 and maximum delay for invention > 5 hours. Moreover, it suggests that “with mechanical thrombectomy” is potential favorable factor for improving aICH in comparison with general treatment.

Abbreviations: aICH = asymptomatic intracerebral hemorrhage, AIS = acute ischemic stroke, CI = confidence interval, EVT = endovascular treatment, I² = inconsistency index, IA = intra-arterial, IV t-PA = intravenous tissue plasminogen activator, LVO = large vessel occlusions, Max = maximum, MeSH = medical subject headings, mRS = modified ranking scale, MT = mechanical thrombectomy.
thrombectomy, NIHSS = National Institutes of Health Stroke Scale, NLR = neutrophil-to-lymphocyte ratio, OR = odds ratio, RCT = randomized controlled trials, sICH = symptomatic intracerebral hemorrhage, vs = versus.

**Keywords:** endovascular treatment, intracranial hemorrhages, IV t-PA, stroke

## 1. Introduction

Stroke is a leading cause of death and disability worldwide, especially in the current aging society.[1] Thrombolytic therapy with intravenous tissue plasminogen activator (IV t-PA) has saved massive acute ischemic stroke (AIS) patients by promoting thrombolysis and reopening of the occluded blood vessels. Therefore, IV t-PA has been recommended as the standard medical treatment and it is the only drug approved by the Federal Drug Administration for AIS.[2,3] Unfortunately, IV t-PA has clinical effect only in the first 3.0 to 4.5 hours after the onset of stroke, after which the possibility of neurological and functional recovery decreases dramatically. In contrast, the short therapeutic window and the extensive set of clinical eligibility criteria for administration limit the application of IV t-PA.

In view of the narrow time limit of IV t-PA, endovascular treatment (EVT) focusing on relieving vessel occlusion in stroke has been developed as an alternative for IV t-PA or as an adjunct in the management over the past few years.[4,5] EVT, including intra-arterial (IA) thrombolysis, intravascular stent, and mechanical thrombectomy (MT), has shown significant superiority in the recanalization rate. However, the disadvantage of the long time for administration hinders the development of EVT. As a consequence, the clinical superiority of EVT is skeptical. In parallel with IV t-PA, EVT has been associated with a higher likelihood of recanalization; however, evidence from nine trials has shown no significant superiority of EVT compared with general treatment (only medication, including intravenous heparin in AIS).

## 2. Methods

### 2.1. Study protocol

This meta-analysis was performed in accordance with the preferred reporting items for systematic reviews and meta-analyses statement (Additional file 1).[26]

### 2.2. Eligibility criteria

Studies were included if they were prospective randomized controlled trials (RCTs) published in English that fulfilled the following criteria:

1. Studies compared EVT (intervention group) with general treatment (control group) including intravenous t-PA and heparin in AIS.
2. All studies were limited to those involving human subjects.
3. If duplicate studies with an accumulating number of patients or something else were published, only the most complete studies were included in the analysis performed in this study.
4. Study populations were not less than 25 patients.
5. Study with only IA thrombolysis in EVT group was excluded.
6. Patients suffered from stroke due to major vessel occlusion, which was confirmed by imaging examination, and had received treatment with EVT or general treatment or both.
7. Studies reported the following outcomes: all-cause mortality or functional outcome measured by modified Rankin Scale (mRS) or symptomatic intracerebral hemorrhage (sICH) or asymptomatic intracerebral hemorrhage (aICH).
8. There were no restrictions on the information of EVT and general treatment, year of the study, patient age, imaging criteria, and National Institutes of Health Stroke Scale (NIHSS) score.

### 2.3. Literature search strategy

PubMed, Scopus and Web of Science were searched for studies published or presented on or before February 5, 2019. All publications are in English. To achieve maximum sensitivity of the search strategy and to include more extensive studies, Medical Subject Headings (MeSH) terms and the keywords that were retrieved in the field of Title/Abstract were used in combination. The search strategy consisted of three parts. “Endovascular” was selected in the MeSH term and “Endovascular treatment”, “Endovascular procedures”, “Endovascular therapy”, “Intra-arterial”, “Thrombectomy”, “Thrombolysis” were retrieved in the field of Title/Abstract. All the above were connected by “OR”. “Stroke” was selected in the MeSH term. Then, “Randomized controlled trial” was selected in the MeSH term. Ultimately, “AND” was used to connect the three parts. All relevant articles were retrieved first, and then irrelevant articles were manually excluded through title and abstract screening and full-text assessment. In addition, special attention was paid to the references of included studies to identify more candidate studies. All work was conducted independently by two investigators to avoid selection bias.

### 2.4. Data extraction and quality assessment

All data were extracted independently from the tables and figures of included studies by two investigators in an unblinded fashion. Moreover, another investigator took responsibility for the accuracy and reliability of all of the extracted data. NIHSS, serving as a predictive tool of the functionality of the AIS patient, is the most widespread clinical scale.[27] Therefore, the study characteristics (author, publication year, study period, country, number of medical centers, and study design), main characteristics of the patients (age, gender, and NIHSS), information on the intervention, outcome measure, maximum delay in the intervention and outcome of the intervention (mRS, intracerebral hemorrhage, and all-cause mortality), and control groups were extracted independently by two authors. The quality of the included studies was assessed by two other authors using the Cochrane Risk of Bias tool.[28]
2.5. Outcome measure

The mRS is an evaluation tool to assess the clinical poststroke functional independence (detailed grades of mRS: 0 - No symptoms; 1 - No significant disability; 2 - Slight disability; 3 - Moderate disability; 4 - Moderately severe disability; 5 - Severe disability; 6 - Dead) [29,30]. The prespecified primary outcome measures were the mRS score of 0–1 and the mRS score 0–2 at 90 days. In addition, a 90-day mRS score of 0–1 and a 90-day mRS score of 0–2 were defined as an excellent outcome and a good outcome, respectively. The prespecified secondary outcome measures were intracerebral hemorrhage and all-cause mortality at 90 days.

2.6. Statistical analysis

Statistical analysis was conducted using Review Manager version 5.2 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) and STATA 12.0 (Stata Corp LP, College Station, TX, USA). The combined effect of odds ratio (OR) and 95% confidence interval (CI) were defined by a random-effect model or a fixed-effect model. The heterogeneity among included studies was tested using the inconsistency index ($I^2$). A random effect model was used when there was a high level of heterogeneity. Publication bias was evaluated qualitatively by visual observation of funnel graphs and was assessed quantitatively by the Begg’s rank correlation method (Stata 12.0), which indicated a publication bias with P < 0.05. A P value of < 0.05 was considered statistically significant. For indicators with high heterogeneity, sensitivity analysis was carried out with the Stata 12.0 software to identify the origin of heterogeneity and reliability of the meta-analysis. In addition, included studies were excluded one by one to perform sensitivity analysis. Subgroup analysis were utilized to uncover the effect of maximum (max) delay for intervention, stroke severity, age and MT on EVT.

3. Results

3.1. Eligible studies and study characteristics

Detailed steps of the inclusion and exclusion criteria of the study are shown in Fig. 1. Briefly, a total of 6301 studies were retrieved from four electronic database searches. Twenty-one additional studies were identified from the references of included studies after removing the duplicates. After the layer-by-layer screening, the final meta-analysis was performed after complete evaluation of 18 studies that met the inclusion criteria.[8–25] The basic characteristics of the included studies and patients are summarized and shown in Tables 1 and 2, respectively. A total of 3831 patients were enrolled in the 18 included studies. The included studies were evaluated objectively and the quality of included studies was proved to be generally high (Table 3).

3.2. Primary outcome

The excellent outcome, mRS 0–1 at 90 days, was observed after EVT (Fig. 2A). A significant difference was found in mRS 0–1 after 90 days between EVT and general treatment (OR = 1.68, 95% CI = 1.43–1.97, $I^2$ = 57%, P < .00001). Another primary outcome measure, mRS 0–2 at 90 days, was favored in the intervention group (Fig. 2B). In comparison with the control group, the intervention group showed a statistically significant difference in mRS 0–2 at 90 days (OR = 1.78, 95% CI = 1.55–2.03, $I^2$ = 69%, P < .00001).

3.3. Secondary outcome

For all-cause mortality at 90 days, all 18 included studies were analyzed. A statistically significant difference was identified between EVT and general treatment (OR = 0.82, 95% CI = 0.70–0.98, $I^2$ = 27%, P = .03) (Fig. 3). Compared to general treatment, EVT had a statistically significant but no positive effect on ICH (OR = 1.28, 95% CI = 1.03–1.60, $I^2$ = 0%, P = .02) (Fig. 4). EVT group had no advantage over the general treatment group for AIS patients in decreasing the risk of sICH (OR = 1.16, 95% CI = 0.85–1.57, $I^2$ = 0%, P = .36) and aICH (OR = 1.43, 95% CI = 1.03–1.95, $I^2$ = 32%, P = .02) (Fig. 4).

3.4. Subgroup analysis

3.4.1. Max delay for intervention. Regardless of max delay for intervention, EVT improved excellent and good functional outcomes but, by contrast, had higher rates of sICH and death. Compared with EVT, general treatment within 5 hours exhibited better effect on improving aICH (OR = 1.65, 95% CI = 1.10–2.45, P = .006; Table 4). There was a modest tendency that EVT might decrease the risk of death (OR = 0.78, 95% CI = 0.61–1.00, P = .05; Table 4).

3.4.2. Stroke severity. Stroke severity from stroke onset did not affect EVT to improve functional outcome, and patients whose NIHSS was beyond 20 have lower rate of death in EVT group (OR = 0.77 95% CI = 0.61–0.98, P = .03; Table 4). However, the low stroke severity subgroup had lower risk of aICH in control group (OR = 1.55, 95% CI = 1.09–2.22, P = .02; Table 4).

3.4.3. Age. No matter whether patients were over 70 years old or not, those who received EVT might get better functional outcome. Age did not affect the effect of EVT and general treatment on ICH. In addition, the risk of death decreased in EVT group when patients were not over 70 years old (OR = 0.75, 95%, CI = 0.58–0.97, P = .03; Table 4).

3.4.4. With/without MT. EVT can improve functional outcomes with or without MT. But only with MT, can EVT significantly decrease risk of aICH (With MT: OR = 0.19, 95% CI = 0.09–0.37, P < .00001; Without MT: OR = 1.65, 95%, CI = 1.10–2.45, P = .01; Table 4).

3.5. Sensitivity analysis

Sensitivity analysis was performed by omitting one study by turns, which showed that Broderick et al [19] and Ciccone et al [11] had a great influence on the pooled ORs (Fig. 5).

3.6. Publication bias

No potential publication bias among the 18 included studies was noted in this meta-analysis when assessed qualitatively and quantitatively with funnel graphs (Fig. 6) and Begg test (Table 5), respectively.

4. Discussion

This study analyzed 18 RCTs comprising 3831 patients to evaluate the outcome in patients who were diagnosed with stroke by imaging examination and who received either EVT or general treatment. This meta-analysis was aimed at summarizing the
benefits of EVT and exploring underlying indications of EVT for AIS patients. A total of 553 of 1885 patients (29.3% versus [vs] 19.6%) with EVT obtained excellent outcome at 90 days, and 919 of 2022 patients (45.5% vs 31.6%) with EVT achieved good outcome. Notably, the results of mRS score demonstrated that EVT resulted in improved mRS and higher likelihood of functional independence at 90 days, compared to general treatment. Furthermore, there was a tendency that patients who were randomized to receive EVT had greater chance of showing a significant decrease in the rate of all-cause mortality (16.9% vs 19.2%) compared to those who were randomized to receive general treatment. This study showed no significant difference in sICH at 90 days (P = .36) but the other way around in aICH (P = .02). Taken together, these results showed strong implications for the development and exploration of EVT, and they also suggested that EVT, which serves as a crucial treatment strategy, enabled patients to recover after stroke.

It is an inaccurate belief that minor or mild stroke with low NIHSS scores is closely related to good functional outcomes. Accumulating studies demonstrated that patients with minor or mild stroke were more likely to suffered from poor functional outcomes and high rate of mortality.\cite{31-34} Actually, AIS with low NIHSS score, defined as minor or mild stroke, appeared to be accompanied with large vessel occlusions (LVO). The STOP Stroke Study, a prospective imaging-based study of stroke outcomes, included 735 patients (mean NIHSS, 7.6), and reported that LVO was associated with negative predictions of functional outcomes (OR = 0.33; 95% CI = 0.24–0.45; P < .001) and 6-month mortality (OR = 4.5; 95% CI = 2.7–7.3; P < .001).\cite{35} Zhu et al\cite{36} found that 51 patients with severe

Figure 1. Study search and selection flow diagram.
| Study | Study period | Region | Medical trial center | Study design | Intervention | Control therapy | Max delay for intervention (h) | EVT information | Control (n) |
|-------|-------------|--------|----------------------|--------------|--------------|----------------|--------------------------|----------------|------------|
| Ciccone et al (2013) [11] | 2008–2012 | Italy | Not stated | RCT | IV t-PA+EVT | IV t-PA | 6 | IA thrombolysis; Mechanical clot disruption | 181 |
| Campbell et al (2015) [19] | 2012–2014 | Australia, New Zealand | 14 | RCT | IV t-PA+EVT | IV alteplase | 6 | Solitaire Flow restoration retrievable stent | 35 |
| Goyal, et al (2015) [21] | 2013–2014 | Canada, USA, South Korea, Europe | 22 | RCT | IV t-PA+EVT | IV alteplase | 12 | Stent retrievers; Solitaire Flow restoration | 164 |
| Jovin et al (2015) [22] | 2012–2014 | Catalonia, Spain | 4 | RCT | IV t-PA+EVT | IV alteplase | 4 | Stent retriever; Solitaire Flow restoration | 103 |
| Jeffrey et al (2015) [23] | 2012–2014 | USA, Europe | 39 | RCT | IV t-PA+EVT | IV t-PA | 6 | Stent retriever; Solitaire Flow Restoration; IA t-PA | 98 |
| Broderick et al (2013) [24] | 2006–2012 | USA, Canada, Australia, Europe | 58 | RCT | IV t-PA+EVT | IV t-PA | 5 | Mechanical thrombectomy | 415 |
|刘等 (2013) [25] | Not stated | Not stated | Not stated | RCT | IV rt-PA and/or intraarterial IA rt-PA and/or mechanical thrombectomy | IV rt-PA | 4.5 | Mechanical thrombectomy; IA thrombolysis; | 123 |
| Sedar et al (2014) [26] | Not stated | Not stated | Not stated | RCT | IV rt-PA | IV alteplase | 3 | Mechanical thrombectomy | 14 |
| Kidwell et al (2013) [27] | 2004–2011 | USA | 22 | RCT | EVT | IV t-PA | 8 | Mechanical embolectomy | 64 |
| Ciccone et al (2010) [28] | Not stated | Not stated | Not stated | RCT | EVT+IV t-PA | IV t-PA | 6 | Mechanical embolectomy | 25 |
| Berkhemer et al (2015) [29] | 2010–2014 | Europe | 16 | RCT | IA thrombolysis+ IV t-PA | IV t-PA | 6 | Mechanical embolectomy; Stent retriever | 233 |
| Ogawa et al (2007) [30] | 2002–2005 | Japan | 57 | RCT | Mechanical disruption+IA urokinase | IV t-PA | 6 | Mechanical thrombectomy; IA urokinase | 57 |
| Qureshi et al (2017) [31] | Not stated | Not stated | Not stated | RCT | IV t-PA+EVT | IV rt-PA | 6 | Mechanical thrombectomy | 34 |
| Khoury et al (2017) [32] | 2013–2014 | Canada | 1 | RCT | IV t-PA+EVT | IV rt-PA | 4 | Mechanical thrombectomy; | 40 |
| Bracard et al (2016) [33] | 2010–2015 | French | 26 | RCT | IV alteplase+EV | IV rt-PA | 6 | Mechanical thrombectomy; IA alteplase | 200 |
| Mocco et al (2016) [34] | 2012–2014 | USA, Germany | 36 | RCT | IV alteplase+EV | IV t-PA | 6 | Aspiration thrombectomy | 62 |
| Nogueira et al (2018) [35] | 2014–2017 | USA, Canada, Europe, Australia | 26 | RCT | IV t-PA+ thrombectomy | IV t-PA | 24 | Thrombectomy | 107 |
| Albers et al (2018) [36] | Not stated | USA | 38 | RCT | IV t-PA+ thrombectomy | IV t-PA | 4.5 | Thrombectomy | 92 |

EVT = endovascular treatment, IA = intra-arterial, IV = intravenous, Max = maximum, RCT = randomized controlled trials.
NIHSS patients had significantly more favorable outcome compared with those with LVO (49.0% vs 27.9%, \(P=0.021\)). There was no significant interaction between LVO and stroke severity on favorable outcome (\(P=0.906\)). These studies came to a consistent conclusion that LVO were independent from stroke severity, and LVO were closely related to poor functional outcomes and high rate of mortality. Hence, appropriate treatment measures are dependent on the situation of cerebral vessel occlusion rather than the stroke severity. In subgroup meta-analysis, results suggested that EVT improved survival rate of patients with NIHSS scores \(\geq 20\). However, it also uncovered a trend that EVT might deteriorate aICH for patients with NIHSS scores < 20. Further researches on the cause of ICH and how to avoid ICH are needed to excavate, which can guide EVT to better treat patients. It is debated whether MT is associated with a higher risk of ICH. Some studies indicated that MT resulted in higher risk of ICH,\(^{37,38}\) but others suggested the situation rather than just the other way around.\(^{39,40}\) In subgroup analysis, it suggested that MT had little effect on the occurrence of sICH, which was not in accordance with other studies. This may be due to the other various EVT information accompanied with MT in included studies. In addition, patients with LVO stroke treated with intravenous thrombolysis alone were often accompanied with a low recanalization rate.\(^{41}\) EVT is focused on relieving

\[
\text{Table 2}
\]

Characteristics of patients included in the randomized controlled trials.

| Study                  | Endovascular Treatment | General Treatment |
|------------------------|------------------------|-------------------|
|                        | Patients, N | Male, N | Age, yr (IQR or SD) | NIHSS Score (IQR or SD) | Patients, N | Male, N | Age, yr (IQR or SD) | NIHSS Score (IQR or SD) |
| Ciccione et al (2013)\(^{11}\) | 123        | 59      | 68.6 ± 16.4 | 161 ± 7.3 | 25  | 19      | 60.6 ± 13.7 | 17 (11-19) |
| Bracard et al (2016)\(^{8}\)   | 14         | 7       | 62 (64-68) | 19 (15-22) | 16   | 7       | 61 (74-88) | 18 (14-21) |
| Kidwell et al (2013)\(^{14}\) | 64         | 30      | 66.6 ± 13.2 | 17 (13-21) | 54   | 27      | 69.4 ± 15.9 | 16 (11-18) |
| Nogueira et al (2018)\(^{20}\) | 107        | 42      | 69.4 ± 14.1 | 17 (13-21) | 99   | 51      | 70.2 ± 13.2 | 17 (14-21) |
| Albers et al (2018)\(^{16}\) | 92         | 46      | 67 (59-79) | 16 (10-20) | 90   | 44      | 71 (59-80) | 16 (12-21) |

IQR=inter-quartile range, NIHSS=National Institutes of Health Stroke Scale, SD=standard deviation.

\[
\text{Table 3}
\]

Cochrane assessment of bias risk of randomized controlled trials.

| Study                  | Randomization sequence generation | Allocation concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome data | Selective outcome reporting | Other sources of bias |
|------------------------|----------------------------------|------------------------|--------------------------------------|-----------------------------|------------------------|--------------------------|------------------------|
| Ciccione et al (2013)\(^{11}\) | Low                              | High                   | Low                                  | Low                         | Low                    | Low                      | High                   |
| Campbell et al (2015)\(^{19}\)    | Low                              | Low                    | Low                                  | Low                         | Low                    | Low                      | Low                    |
| Goyal et al (2015)\(^{21}\)       | Low                              | Low                    | Low                                  | Low                         | Low                    | Low                      | Low                    |
| Joivin et al (2015)\(^{22}\)     | Low                              | Low                    | Low                                  | Low                         | Low                    | Low                      | Low                    |
| Jeffrey et al (2015)\(^{25}\)   | Low                              | Low                    | Low                                  | Low                         | Low                    | Low                      | Low                    |
| Broderick et al (2013)\(^{9}\)  | Low                              | Unclear                | Low                                  | Low                         | Low                    | Low                      | Low                    |
| Rai et al (2013)\(^{24}\)       | Low                              | Low                    | Not stated                           | Low                         | Low                    | Low                      | Low                    |
| Senard et al (2014)\(^{12}\)   | Low                              | Low                    | Not stated                           | Low                         | Low                    | Low                      | Low                    |
| Kidwell et al (2013)\(^{14}\)   | Low                              | Low                    | Not stated                           | Low                         | Low                    | Low                      | Low                    |
| Ciccione et al (2013)\(^{10}\) | Low                              | Low                    | Low                                  | Low                         | Low                    | Low                      | Low                    |
| Berkhemer et al (2015)\(^{14}\) | Low                              | Low                    | Low                                  | Low                         | Low                    | Low                      | Low                    |
| Ogawa et al (2007)\(^{17}\)    | Low                              | Low                    | Low                                  | Low                         | Low                    | Low                      | Low                    |
| Qureshi et al (2017)\(^{23}\)  | Low                              | Low                    | Low                                  | Low                         | Low                    | Low                      | Low                    |
| Khoury et al (2017)\(^{13}\)   | Low                              | Low                    | Low                                  | Low                         | Low                    | Low                      | Low                    |
| Bracard et al (2016)\(^{8}\)   | Low                              | Low                    | Low                                  | Low                         | Low                    | Low                      | Low                    |
| Mocco et al (2016)\(^{15}\)    | Low                              | Low                    | Low                                  | Low                         | Low                    | Low                      | Low                    |
| Qureshi et al (2017)\(^{23}\)  | Low                              | Low                    | Low                                  | Low                         | Low                    | Low                      | Low                    |
| Albers et al (2018)\(^{16}\)   | Low                              | Low                    | Low                                  | Low                         | Low                    | Low                      | Low                    |

\[
\text{Albers et al (2018)\(^{16}\)   | Low                              | Low                    | Low                                  | Low                         | Low                    | Low                      | Low                    |
\]
vessel occlusion and is associated with improved functional outcomes and cerebral microcirculation. Moreover, aICH, considered as indicative of microangiopathy, is a specific marker for previous bleeding from pathologically fragile cerebral small vessels. Therefore, the subgroup analysis on aICH uncovered a novel discovery that MT can effectively reduce the occurrence of aICH. Simultaneously, EVT often involves in larger doses of IV t-PA and cerebral hyperperfusion might result in poor clinical outcomes, so that the risk of sICH and mortality increased. However, EVT with MT appeared to have no negative effects on the risk of sICH and survival rate in subgroup analysis. Compared to general treatment, the subgroup analysis on max delay for intervention showed a modest tendency that EVT was more effective and safer for stroke patients whose max delay for intervention were beyond 5 hours. Patients with age <70 appeared to have better survival rate in EVT group, which was inconsistent with some studies. In fact, these studies were relatively small sample sizes in paralleled with this meta-analysis. Hilditch et al included 860 patients aged 80 years or older who were treated with EVT for AIS. Pooled data demonstrated that octogenarians treated with EVT had better chances of obtaining an improved functional outcome, compared with patients not treated with EVT. However, outcomes of octogenarians were still inferior to those reported for younger patients. In addition, Goyal et al included 5 RCTs of EVT, and reported good functional outcomes in 46% of patients and a mortality rate of 15%. However, among patients who were over 80 years in the EVT group, the rates were 29.8% for good functional outcome and 28% for mortality at 90 days. Another study show that there was no significant difference in sICH between octogenarians and younger patients (P=.32), whereas octogenarians had a lower rate of good clinical outcome (24% vs 48%; P=.008) and a higher rate of mortality (36% vs 12%; P=.0013). Patient selection should be identified by various
Table 1. Characteristics of included studies of the intervention and control groups.

| Study of Subgroup | Endovascular Treatment | Control | Odds Ratio |
|------------------|------------------------|---------|------------|
|                  | Total | Events | Total | Events | Total | Events | Weight | M.H. Fixed, 95% CI |
|                  |       |        |       |        |       |        |        |                  |
| Albers 2018      | 13    | 92     | 23    | 90     | 6.8%  | 0.49   | [0.23, 1.02] |
| Berkhemer 2015   | 49    | 233    | 59    | 267    | 14.7% | 0.94   | [0.61, 1.44] |
| Bracard 2016     | 24    | 200    | 27    | 202    | 8.0%  | 0.88   | [0.49, 1.59] |
| Broderick 2013   | 83    | 415    | 48    | 214    | 17.1% | 0.86   | [0.58, 1.29] |
| Campbell 2015    | 3     | 35     | 35    | 29     | 1.2%  | 1.52   | [0.40, 5.74] |
| Ciccone 2013     | 6     | 25     | 11    | 36     | 1.9%  | 1.52   | [0.60, 4.03] |
| Ciccone 2013     | 28    | 181    | 101   | 118    | 6.2%  | 1.52   | [0.60, 2.96] |
| Goyal 2015       | 17    | 164    | 28    | 147    | 0.9%  | 0.69   | [0.26, 1.84] |
| Jeffrey 2015     | 9     | 98     | 12    | 93     | 3.8%  | 0.92   | [0.75, 1.13] |
| Jovin 2015       | 19    | 103    | 12    | 103    | 4.4%  | 1.23   | [0.59, 2.55] |
| Khoury 2017      | 11    | 40     | 9     | 37     | 2.3%  | 1.18   | [0.42, 3.28] |
| Kidwell 2013     | 12    | 64     | 7     | 54     | 2.1%  | 1.55   | [0.56, 4.26] |
| Marco 2018       | 3     | 37     | 10    | 41     | 2.6%  | 1.32   | [0.27, 1.10] |
| Nogueira 2018    | 20    | 107    | 18    | 99     | 5.1%  | 1.83   | [0.53, 2.01] |
| Ogawa 2007       | 3     | 57     | 2     | 57     | 0.6%  | 1.95   | [0.25, 9.51] |
| Qureshi 2017     | 3     | 34     | 3     | 17     | 2.5%  | 0.11   | [0.02, 0.65] |
| Raji 2013        | 39    | 123    | 44    | 100    | 11.2% | 0.59   | [0.34, 0.92] |
| Serdar 2014      | 2     | 14     | 3     | 16     | 0.8%  | 0.72   | [0.10, 5.09] |
| Total (95% CI)   | 2022  | 1782   | 100.0%|        |        | 0.82   | [0.70, 0.98] |
| Total events     | 341   |        | 342   |        |        |        |        |                  |

Heterogeneity: Chi² = 23.29, df = 17 (P = 0.14); I² = 27%
Test for overall effect: Z = 2.24 (P = 0.03)

Figure 3. Forest plot of all-cause mortality in the intervention and control groups.

Table 2. Characteristics of included studies of the subgroup meta-analysis of sICH and aICH in the intervention and control groups.

| Study of Subgroup | Endovascular Treatment | Control | Odds Ratio |
|------------------|------------------------|---------|------------|
|                  | Total | Events | Total | Events | Total | Events | Weight | M.H. Fixed, 95% CI |
|                  |       |        |       |        |       |        |        |                  |
| 1.4.1 sICH       | 100   | 100    | 75    |        | 2.6%  | 1.50   | [0.41, 5.50] |
| Albers 2018      | 6     | 92     | 4     | 90     | 2.6%  | 1.50   | [0.41, 5.50] |
| Berkhemer 2015   | 18    | 233    | 17    | 267    | 10.2% | 1.23   | [0.62, 2.45] |
| Bracard 2016     | 4     | 195    | 3     | 192    | 2.0%  | 1.39   | [0.31, 6.31] |
| Broderick 2013   | 27    | 415    | 13    | 214    | 11.2% | 1.06   | [0.54, 2.13] |
| Campbell 2015    | 0     | 35     | 2     | 35     | 1.7%  | 0.19   | [0.01, 4.09] |
| Ciccone 2013     | 10    | 181    | 10    | 181    | 6.6%  | 1.00   | [0.41, 2.46] |
| Goyal 2015       | 6     | 164    | 4     | 147    | 2.6%  | 1.36   | [0.38, 4.91] |
| Jeffrey 2015     | 7     | 98     | 3     | 93     | 2.5%  | 0.13   | [0.01, 2.58] |
| Jovin 2015       | 3     | 40     | 2     | 37     | 1.3%  | 1.42   | [0.22, 9.01] |
| Khoury 2017      | 7     | 103    | 4     | 103    | 2.6%  | 1.80   | [0.51, 6.30] |
| Kidwell 2013     | 3     | 64     | 2     | 54     | 1.4%  | 1.28   | [0.21, 7.95] |
| Mocco 2016       | 6     | 62     | 4     | 43     | 3.0%  | 1.04   | [0.28, 3.95] |
| Nogueira 2018    | 6     | 107    | 3     | 99     | 2.0%  | 1.90   | [0.48, 7.82] |
| Serdar 2014      | 2     | 14     | 0     | 16     | 0.3%  | 6.60   | [0.29, 150.07] |
| Subtotal (95% CI)| 1818  | 1600   | 52.6% |        | 1.16   | [0.85, 1.57] |
| Total events     | 100   |        | 75    |        |        |        |        |                  |

Heterogeneity: Chi² = 6.75, df = 14 (P = 0.94); P = 0%
Test for overall effect: Z = 0.92 (P = 0.36)

1.4.2 aICH

| Study of Subgroup | Endovascular Treatment | Control | Odds Ratio |
|------------------|------------------------|---------|------------|
|                  | Total | Events | Total | Events | Total | Events | Weight | M.H. Fixed, 95% CI |
|                  |       |        |       |        |       |        |        |                  |
| Broderick 2013   | 119   | 415    | 42    | 214    | 27.5% | 1.65   | [1.10, 2.45] |
| Jovin 2015       | 17    | 103    | 11    | 102    | 6.4%  | 1.65   | [0.72, 3.73] |
| Khoury 2017      | 6     | 40     | 10    | 37     | 6.1%  | 0.48   | [0.15, 1.48] |
| Kidwell 2013     | 19    | 64     | 14    | 54     | 7.4%  | 1.21   | [0.54, 2.71] |
| Subtotal (95% CI)| 622   | 408    | 47.4% |        | 1.43   | [1.05, 1.95] |
| Total events     | 181   |        | 77    |        |        |        |        |                  |

Heterogeneity: Chi² = 4.40, df = 3 (P = 0.22); P = 32%
Test for overall effect: Z = 2.24 (P = 0.02)

Figure 4. Forest plot of the subgroup meta-analysis of sICH and aICH in the intervention and control groups.


| Table 4 |

Subgroup analysis of endovascular treatment and general treatment in primary outcomes and secondary outcomes.

| Max delay for intervention (hours) | Excellent | P value | Good outcome | P value |
|-----------------------------------|-----------|---------|--------------|---------|
| Time > 5h                          | 1.61 (1.43, 2.30) | .0001 | 1.90 (1.59, 2.27) | .0001 |
| Time ≤ 5h                          | 1.40 (1.09, 1.73) | .007 | 1.67 (1.36, 2.04) | .0001 |
| Stroke severity at baseline        | 1.90 (1.47, 2.46) | .0001 | 2.06 (1.69, 2.51) | .0001 |
| NIHSS ≥ 20                         | 1.30 (1.08, 1.91) | .0001 | 1.88 (1.34, 1.92) | .0001 |
| NIHSS < 20                         | 1.24 (1.04, 1.48) | .0001 | 1.75 (1.45, 2.12) | .0001 |
| Age (years)                        | 1.47 (1.18, 1.84) | .007 | 1.89 (1.52, 2.15) | .0001 |
| Age ≥ 70                           | 1.56 (1.26, 1.93) | .003 | 1.49 (1.14, 1.94) | .003 |
| Age ≤ 70                           | 1.30 (1.09, 1.52) | .016 | 1.45 (1.14, 1.86) | .003 |
| With/without MT                    | 1.54 (1.17, 2.09) | .003 | 1.49 (1.14, 1.94) | .003 |

**Primary outcomes**

**Secondary outcomes**

| Max delay for intervention (hours) | aICH | P value | sICH | P value | Death | P value |
|-----------------------------------|------|---------|------|---------|-------|---------|
| Time > 5h                          | 0.99 (0.58, 1.69) | .69 | 0.99 (0.46, 1.68) | .81 | 0.86 (0.68, 1.09) | .22 |
| Time ≤ 5h                          | 1.65 (1.10, 2.46) | .006 | 1.65 (1.15, 2.36) | .24 | 0.78 (0.61, 1.00) | .05 |
| Stroke severity at baseline        | 1.08 (1.07, 2.04) | .82 | 1.30 (0.88, 1.91) | .18 | 0.77 (0.61, 0.98) | .03 |
| NIHSS ≥ 20                         | 1.55 (1.09, 2.22) | .02 | 0.97 (0.54, 1.76) | .93 | 0.92 (0.72, 1.18) | .52 |
| NIHSS < 20                         | 1.30 (1.09, 1.88) | .16 | 1.45 (0.76, 2.76) | .26 | 0.75 (0.58, 0.97) | .03 |
| Age (years)                        | 1.41 (0.80, 2.51) | .24 | 1.09 (0.71, 1.67) | .71 | 0.83 (0.66, 1.04) | .11 |
| Age ≤ 70                           | 1.30 (1.09, 1.52) | .16 | 1.45 (0.76, 2.76) | .26 | 0.75 (0.58, 0.97) | .03 |
| With/without MT                    | 0.19 (0.09, 0.37) | < .0001 | 1.27 (0.84, 1.90) | .25 | 0.88 (0.71, 1.09) | .26 |
| Without                            | 1.65 (1.10, 2.46) | .01 | 0.86 (0.49, 1.50) | .59 | 0.73 (0.52, 1.03) | .07 |

aICH = asymptomatic intracerebral hemorrhage, CI = confidence interval, MT = mechanical thrombectomy, NIHSS = National Institutes of Health Stroke Scale, OR = odds ratio, sICH = symptomatic intracerebral hemorrhage.

**Factors, especially when considering octogenarians for EVT.**

Taken together, these results were comparable with those obtained by our meta-analysis of 18 included studies.

ICH accounts for approximately 10% to 30% of stroke patients and results in high rates of mortality and functional disability among survivors. Inflammation is one of the main pathogenetic factors in ischemic stroke. Ischemia and reperfusion injury triggered both the production and secretion of inflammatory cytokines and pro-inflammatory cytokines. Early inflammation may be detrimental on the functional outcome. Reactive microglia/macrophages can be observed as early as 2 hours after an ischemic stroke and maintained for up to 1 week. Following activation of peripheral leukocytes and infiltration into the brain, the tight junctions between endothelial cells of the Blood–brain barrier are disrupted and become more permeable. Blood–brain barrier disruption has been suggested as an underlying mechanism for ICH after ischemic stroke. ICH poses a safety concern for EVT, and even may decrease the benefit–risk ratio of EVT. Therefore, it is vital to identify appropriate predictors to evaluate the incidence of ICH after EVT. Accumulating evidence showed that neutrophil-to-lymphocyte ratio (NLR) was associated with an increased risk of ICH and outperformed other predictors. Lattanzi et al. included 177 patients and reported that higher neutrophils (OR = 1.22, 95% CI = 1.03–1.44, P = .023) and lower lymphocytes (OR = 0.57, 95% CI = 0.33–0.99, P = .046) independently associated with poor ICH outcome. A prospective study (n = 58 including 28 thrombolytic patients, 10 patients subjected to thrombectomy following thrombolysis, and 20 patients assigned to no causal treatment) reported significantly high NLR in those treated with thrombolysis and thrombectomy compared to the other groups (P = .03). The results might be related to increased severity of the disease in these patients. However, the relationship between the severity of inflammation, evidenced by increased NLR, and the outcome of stroke treatment remains vague and worth exploring. Overall, NLR played a vital role in the risk stratification of AIS patients for EVT and decreasing risk of ICH after EVT.

In view of the medium heterogeneity in excellent outcome (mRS 0–1) and good outcome (mRS 0–2), sensitivity analysis was performed. After excluding Broderick et al. and Ciccnone et al. from the meta-analysis of excellent outcome, F changed from 57% to 7%. In Broderick et al. [9], loss to follow-up and randomized grouping (participants without angiographic evidence of a treatable occlusion received no additional treatment, but those with a treatable vascular occlusion received EVT) might cause heterogeneity. In Ciccnone et al., no patient was lost to follow-up and dropped out of the trial, whereas 15 of the 181 patients randomized to EVT group did not receive the treatment, which might result in heterogeneity. Moreover, when Broderick et al. and Ciccnone et al. excluded patients that did not have the *treatment, it is vital to identify appropriate predictors to evaluate the incidence of ICH after EVT.**

In view of medium heterogeneity in excellent outcome (mRS 0–1) and good outcome (mRS 0–2), sensitivity analysis was performed. After excluding Broderick et al. and Ciccnone et al. from the meta-analysis of excellent outcome, F changed from 57% to 7%. In Broderick et al. [9], loss to follow-up and randomized grouping (participants without angiographic evidence of a treatable occlusion received no additional treatment, but those with a treatable vascular occlusion received EVT) might cause heterogeneity. In Ciccnone et al., no patient was lost to follow-up and dropped out of the trial, whereas 15 of the 181 patients randomized to EVT group did not receive the treatment, which might result in heterogeneity. Moreover, when Broderick et al. and Ciccnone et al. excluded patients that did not have the *treatment, it is vital to identify appropriate predictors to evaluate the incidence of ICH after EVT.**

In view of medium heterogeneity in excellent outcome (mRS 0–1) and good outcome (mRS 0–2), sensitivity analysis was performed. After excluding Broderick et al. and Ciccnone et al. from the meta-analysis of excellent outcome, F changed from 57% to 7%. In Broderick et al. [9], loss to follow-up and randomized grouping (participants without angiographic evidence of a treatable occlusion received no additional treatment, but those with a treatable vascular occlusion received EVT) might cause heterogeneity. In Ciccnone et al., no patient was lost to follow-up and dropped out of the trial, whereas 15 of the 181 patients randomized to EVT group did not receive the treatment, which might result in heterogeneity. Moreover, when Broderick et al. and Ciccnone et al. excluded patients that did not have the *treatment, it is vital to identify appropriate predictors to evaluate the incidence of ICH after EVT.**

In view of medium heterogeneity in excellent outcome (mRS 0–1) and good outcome (mRS 0–2), sensitivity analysis was performed. After excluding Broderick et al. and Ciccnone et al. from the meta-analysis of excellent outcome, F changed from 57% to 7%. In Broderick et al. [9], loss to follow-up and randomized grouping (participants without angiographic evidence of a treatable occlusion received no additional treatment, but those with a treatable vascular occlusion received EVT) might cause heterogeneity. In Ciccnone et al., no patient was lost to follow-up and dropped out of the trial, whereas 15 of the 181 patients randomized to EVT group did not receive the treatment, which might result in heterogeneity. Moreover, when Broderick et al. and Ciccnone et al. excluded patients that did not have the *treatment, it is vital to identify appropriate predictors to evaluate the incidence of ICH after EVT.**

In view of medium heterogeneity in excellent outcome (mRS 0–1) and good outcome (mRS 0–2), sensitivity analysis was performed. After excluding Broderick et al. and Ciccnone et al. from the meta-analysis of excellent outcome, F changed from 57% to 7%. In Broderick et al. [9], loss to follow-up and randomized grouping (participants without angiographic evidence of a treatable occlusion received no additional treatment, but those with a treatable vascular occlusion received EVT) might cause heterogeneity. In Ciccnone et al., no patient was lost to follow-up and dropped out of the trial, whereas 15 of the 181 patients randomized to EVT group did not receive the treatment, which might result in heterogeneity. Moreover, when Broderick et al. and Ciccnone et al. excluded patients that did not have the *treatment, it is vital to identify appropriate predictors to evaluate the incidence of ICH after EVT.
might account for the heterogeneity caused by Albers et al\[16\]
Nogueira et al\[20\] enrolled patients with larger core infarctions
than other trials and also included patients with milder stroke
symptoms.

Before 2015, there has been some controversy about the
superiority of EVT for the treatment of stroke. Based on
accumulating trials, the mainstream view about the value of EVT
was that EVT is not superior to general treatment.\[8–15\]
Furthermore, the mainstream view was confirmed by results of
meta-analyses.\[60,61\] As opposed to prior meta-analyses, some
subsequent meta-analyses justified the superiority of EVT for
stroke after 2015.\[60,62–65\] However, the justification of benefits
were just limited to improvement of functional outcomes and
functional independence.

Previous meta-analyses were performed with small samples, no
more than 1500 cases, which appeared to have negative effects on
the comparison between EVT and general treatment. In this meta-
analyses, a comprehensive database search was performed, and as
a result, 18 studies comprising a total of 3831 patients were
included. As a large number of cases were included in the
analysis, which was rare in other meta-analyses, there was a
significant decrease in heterogeneity compared with that in other
meta-analyses. Tan et al.\[65\] merged trials of IA thrombolysis
with MT, but the recanalization rate of MT can reach to 70%,
while IA thrombolysis is only about 20%. Therefore, it appeared
to be inappropriate to merge trials of IA thrombolysis with MT,
and we excluded trials of IA thrombolysis in this meta-analysis.
Low or no heterogeneity ensured that this meta-analysis was

Figure 5. Forest plot in the sensitivity analysis of (A) mRS 0–1, (B) mRS 0–2, (C) all-cause mortality, (D) sICH and (E) aICH in AIS.
sufficiently reliable. In addition, EVT significantly reduced the odds of all-cause mortality, which was not found in previous meta-analyses. This analysis was novel, as not only sICH but also aICH was selected as a secondary outcome to perform subgroup analysis. Unfortunately, aICH was considered as a non-significant outcome in previous meta-analyses, but it was placed an indispensable importance in this meta-analysis. Compared to general treatment, our results showed that sICH were not improved by EVT according to the results of this meta-analysis, and a higher rate of aICH was found in patients treated with EVT. It demonstrated that the increasing risk of aICH was the main cause of significantly higher risk of ICH in patients treated with EVT, which was not found in previous meta-analyses. From the perspective of pooled outcomes and subgroup analysis, EVT might entail deteriorated intracerebral hemorrhage, when the max delay for invention of patients with NIHSS < 20 is within 5 hours. This meta-analysis seems to preliminarily clarify the contraindications of EVT.

The quality of the 18 included studies was generally high, and it was confirmed that there was no evidence of publication bias in this meta-analysis. Despite the shining points of this meta-analysis, its limitations and shortcomings should be emphasized. Patients could not be blinded and this may have resulted in patients intervening in most of the trials, which may have led to performance bias. Data were extracted from trials with impressively different designs, in particular with respect to patient enrollment, time to treatment, different drug dosages, and devices, which may have led to diverse biases. Moreover, these included trials had the following notable shortcomings: misdrew, use of different MT devices, and diverse uses of IV t-PA as an adjunct in EVT. In addition, results were incomplete in this meta-analysis. EVT was focused on relieving vessel occlusion and increased the likelihood of recanalization in stroke. Due to the absence of available data in included studies, it was arduous to stratify outcomes on the basis of recanalization rate, stroke onset-to-recanalization time and type of anesthesia used, which devastatingly affected this meta-analysis to further explore underlying indications of EVT for AIS. Meanwhile, the EVT prognosis of patients with NIHSS ≤ 5 could not be performed to obtain, which was widely recognized as mild ischemic stroke.

Table 5
Effect of endovascular treatment on the end points obtained from all 18 included studies.

| End points         | Number of trials | Intervention, n/N (%) | Control, n/N (%) | Pooled OR (95% CI) | Test for publication bias (Begg test) | P value | I^2 |
|--------------------|------------------|-----------------------|------------------|-------------------|---------------------------------------|---------|-----|
| mRS 0–1            | 16               | 553/1885 (29.3%)      | 326/1666 (19.6%) | 1.68 (1.43–1.97)  | 0.964                                 | <.00001 | 57% |
| mRS 0–2            | 18               | 919/2022 (45.5%)      | 564/1782 (31.6%) | 1.78 (1.55–2.03)  | 0.256                                 | <.00001 | 69% |
| All-cause mortality| 18               | 341/2022 (16.9%)      | 342/1782 (19.2%) | 0.82 (0.70–0.98)  | 0.649                                 | =.03    | 27% |
| sICH               | 15               | 100/1818 (5.5%)       | 75/1600 (4.7%)   | 1.14 (0.85–1.57)  | 0.692                                 | =.36    | 0%  |
| aICH               | 4                | 161/622 (25.9%)       | 77/408 (18.9%)   | 1.41 (1.03–1.95)  | 0.308                                 | =.02    | 32% |

aICH = asymptomatic intracerebral hemorrhage, mRS = modified Rankin Scale, n/N = number of patients achieving each end point/number of patients included, OR = odds ratio, sICH = symptomatic intracerebral hemorrhage.
Therefore, the relationship between minor or mild stroke and poor clinical outcomes could not be further presented in this meta-analysis.

Time to recanalization is the major limitation of EVT. It was noted that ESCAPE [22] showed the maximum delay time for recanalization, whereas further trials with positive results showed time to treatment from 3 to 5 hours. Based on computed tomography, a retrospective study reported that a novel EVT might reduce the time to treatment [66]. Also, rapid transfer of patients and popularization of stent retrievers can shorten the treatment time, which may be a research hotspot for exploration and development in the near future.

5. Conclusion
In conclusion, this meta-analysis provides some evidences for improved functional outcome and decreased odds of all-cause mortality following EVT compared with that following general treatment after 90 days from stroke onset. However, EVT might lead to higher risk of ICH, which hampers the application and development of EVT. Moreover, EVT with MT can reduce the occurrence of aICH in AIS patients. Furthermore, this meta-analysis supports currently EVT as a treatment strategy to improve the clinical outcomes in AIS patients with age <70, NIHSS ≥20 and max delay for invention >5 hours, who may benefit the most from EVT. Also, it suggests that “with mechanical thrombectomy” is potential favorable factor for improving aICH in comparison with general treatment. General treatment can play a vital role in clinical treatment of AIS patients through the supplement of EVT. In the near future, RCTs should be devote to providing more data regarding the potential association of EVT with the risk of aICH.

Acknowledgments
We thank LetPub (www.letpub.com) for its linguistic assistance during the preparation of this manuscript.

Author contributions
Conceptualization: Weinan Yang.
Data curation: Weinan Yang, Lincheng Zhang.
Formal analysis: Weinan Yang, Lincheng Zhang.
Funding acquisition: Weinan Yang, Yuyan Zhang, Suqing Zhang, Hong Li.
Investigation: Weinan Yang, Lincheng Zhang.
Methodology: Weinan Yang, Lincheng Zhang, Qiguo Yao.
Project administration: Weiyan Chen, Lan He.
Resources: Lan He, Weiyan Chen, Weijie Yang.
Software: Weinan Yang, Licheng Zhang.
Supervision: Weinan Yang, Licheng Zhang, Yuyan Zhang.
Validation: Yuyan Zhang, Hong Li.
Visualization: Weinan Yang, Licheng Zhang, Yuyan Zhang.
Writing – original draft: Weinan Yang, Lincheng Zhang.
Writing – review and editing: Weinan Yang, Qiguo Yao, Yuyan Zhang.

References
[1] Feigin VL, Roth GA, Naghavi M, et al. Global factors in 188 countries, during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurol 2016;15:913–24.
[2] Hans W, Kielstein JT, Karin W. Response to letter regarding article, “asymmetric dimethylarginine in response to recombinant tissue-type plasminogen activator and erythropoetin in acute stroke.” Stroke 2013;44:e230.
[3] Jauch EC, Saver JL, Adams HP, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870–947.
[4] Lees KR, Erich B, Rüdiger VK, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695–703.
[5] Weintraub MI. Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire. Stroke 2016;37:1917–22.
[6] Meyers PM, Christian H, Sander E, RT, et al. Current status of endovascular treatment. Circulation 2011;123:2591–601.
[7] Pierot L, Soize S, Benaisa A, et al. Techniques for Endovascular Treatment of Acute Ischemic. Stroke 2015;46:909–14.
[8] Bracard S, Ducrocq X, Mas JL, et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. Lancet Neurol 2016;15:1138–47.
[9] Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013;368:893–903.
[10] Ciccone A, Valvassori L, Ponzio M, et al. Intrarreta arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. J Neurol Neurosurg Psychiatry 2010;2:74–9.
[11] Ciccone A, Valvassori L, Michelatti M, et al. Endovascular treatment for acute ischemic stroke. N Engl J Med 2013;368:904–13.
[12] Tutuncu S, Schett JF, Bohner G, et al. Endovascular procedures versus intravenous thrombolysis in stroke with tandem occlusion of the anterior circulation. J Vasc Interv Radiol 2014;25:1165–70.
[13] Khoury NN, Darsaut TE, Ghosh M, et al. Endovascular thrombectomy and medical therapy versus medical therapy alone in acute stroke: A randomized controlled trial. J Neurosurg 2017;14:198–202.
[14] Kidwell CS, Jahan R, Gornbein J, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med 2013;368:914–23.
[15] Mocco J, Zaidat OO, von Kummer R, et al. Aspiration thrombectomy after intravenous alteplase versus alteplase alone. Stroke 2016;47:2331–8.
[16] Albers GW, Marks PS, Kemp S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med 2018;378:708–18.
[17] Ogawa A, Mori E, Minematsu K, et al. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELIT) Japan Stroke. 2007;38:2633–9.
[18] Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;373:211–20.
[19] Campbell BC, Mitchell Pj, Kleintbj, Tj, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015;373:1009–18.
[20] Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy to 24 Hours After Stroke with a Mismatch between Deficit and Infarct. N Engl J Med 2018;378:11–21.
[21] Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015;372:1019–30.
[22] Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015;372:2396–306.
[23] Qureshi AI, Saleem MA, Ayteq C. Comparison of endovascular treatment with intravenous thrombolysis for isolated M2 segment of middle cerebral artery occlusion in acute ischemic stroke. J Vasc Interv Neurol 2017;9:8–14.
[24] Rait AT, Carpenter CA, Kariuki RM, et al. Endovascular therapy yields significantly superior outcomes for large vessel occlusions compared with intravenous thrombolysis: is it time to randomize? J Neurointerv Surg 2013;5:430–4.
[25] Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous alteplase alone. N Engl J Med 2015;372:2391–95.
[26] Mohler D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
[27] Olivato S, Nizzoli S, Cavazzuti M, et al. e-NIHSS: an Expanded National Institutes of Health Stroke Scale Weighted for Anterior and Posterior Circulation Strokes. J Stroke Cerebrovasc Dis 2016;25:293–7.

[28] Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions. Wiley Online Library.

[29] Pego-Pérez ER, Fernández-Rodríguez I, Pumar-Cebreiro JM. National Institutes of Health Stroke Scale, modified Rankin Scale, and modified Thrombolysis in Cerebral Infarction as autonomy predictive tools for stroke patients. Rev Neurol 2019.

[30] Quinn TJ, Taylor-Rowan M, Coyte A, et al. Pre-Stroke Modified Rankin Scale: Evaluation of Validity, Prognostic Accuracy, and Association with Treatment. Front Neurol 2017;8:275.

[31] Khatri P, Conaway MR, Johnston KC. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke. Stroke 2012;43:560–2.

[32] Smith EE, Abdullah AR, Petkovska I, et al. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke 2005;36:2497–9.

[33] Smith EE, Fonarow GC, Reeves MJ, et al. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. Stroke 2011;42:3110–5.

[34] Nedeltchek V, Schweger B, Haefeli T, et al. Outcome of stroke with mild or rapidly improving symptoms. Stroke 2007;38:2531–5.

[35] Smith WS, Lev MH, English JD, et al. Significance of large vessel intracranial occlusion causing acute ischemic stroke and TIA. Stroke 2009;40:3834–40.

[36] Zhu W, Churiiev L, Campbell BC, et al. Does large vessel occlusion affect clinical outcome in stroke with mild neurologic deficits after intravenous thrombolysis? J Stroke Cerebrovasc Dis 2014;23:2888–93.

[37] Haussen DC, Lima FO, Bouslama M, et al. Thrombectomy versus medical management for large vessel occlusion strokes with minimal symptoms: an analysis from STOPStroke and GESTOR cohorts. J Neurointerv Surg 2017;9:1–5.

[38] Dargazanli C, Arquizan C, Gory B, et al. Mechanical Thrombectomy for Minor and Mild Stroke Patients Harboring Large Vessel Occlusion in the Anterior Circulation: A Multicenter Cohort Study. Stroke 2017;48:2746–81.

[39] Haussen DC, Bouslama M, Grossberg JA, et al. Too good to intervene? Thrombectomy for large vessel occlusion strokes with minimal symptoms: an intention-to-treat analysis. J Neurointerv Surg 2017;9:917–21.

[40] Messer MP, Schoenenberger S, Moehlenbruch MA, et al. Minor Stroke Syndromes in Large-Vessel Occlusions: Mechanical Thrombectomy or Thrombolysis Only? AJNR Am J Neuroradiol 2017;38:1177–9.

[41] Seners P, Turc G, Maier B, et al. Incidence and predictors of early recanalization after intravenous thrombolysis: a systematic review and meta-analysis. Stroke 2016;47:2409–12.

[42] Kneihsl M, Niederkorn K, Deuchmann H, et al. Increased middle cerebral artery mean blood flow velocity index after stroke thrombectomy indicates increased risk for intracranial hemorrhage. J Neurointerv Surg 2018;10:882–7.

[43] Kaesmacher J, Kreiser K, Manning NW, et al. Clinical outcome prediction after thrombectomy of proximal middle cerebral artery occlusions by the appearance of lenticulostriate arteries on magnetic resonance angiography: A retrospective analysis. J Cereb Blood Flow Metab 2018;38:1911–23.

[44] Hilditch CA, Nicholson P, Murad MH, et al. Endovascular Management of Acute Stroke in the Elderly: A Systematic Review and Meta-Analysis. AJNR Am J Neuroradiol 2018;39:887–91.

[45] Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 2016;387:1724–31.

[46] Brousseau E, Weymayr F, Hirzel W, et al. Endovascular mechanical recanalization of acute ischaemic stroke in octogenarians. Eur Radiol 2016;26;1742–30.

[47] Feigin VL, Lawes CM, Bennett DA, et al. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003;2:43–53.

[48] Hagberg H, Mallard C, Ferriero DM, et al. The role of inflammation in perinatal brain injury. Nat Rev Neurol 2015;11:192–208.

[49] Chamarro A, Hallenbeck J. The harms and benefits of inflammatory and immune responses in vascular disease. Stroke 2006;37:291–3.

[50] Kim JY, Kawabori M, Yenari MA. Inflammatory responses in stroke: mechanisms and potential therapeutic targets. Curr Med Chem 2014;21:1076–97.

[51] Da Fonseca AC, Matias D, Garcia C, et al. The impact of microglial activation on blood-brain barrier in brain diseases. Front Cell Neurosci 2018;4:362.

[52] Famin BM. The immune response to acute focal cerebral ischemia and associated post-stroke immunodepression: a focused review. Aging Dis 2014;5:307–26.

[53] Trendelenburg G. Molecular regulation of cell fate in cerebral ischemia: role of the inflammasome and connected pathways. J Cereb Blood Flow Metab 2014;34:1857–67.

[54] Krueger M, Bechmann I, Immig K, et al. Blood-brain barrier breakdown involves four distinct stages of vascular damage in various models of experimental focal cerebral ischemia. J Cereb Blood Flow Metab 2015;35:292–303.

[55] Maestri I, Steban D, Gautier S, et al. Higher neutrophil counts before thrombolysis for cerebral ischemia predict worse outcomes. Neurology 2015;85:1408–16.

[56] Lattanzi S, Brigo F, Trinka E, et al. Neutrophil-to-Lymphocyte Ratio Predicts the Outcome of Acute Intracerebral Hemorrhage. Stroke 2019;10:137–45.

[57] Hao Y, Yang D, Wang H, et al. Predictors for Symptomatic Intracranial Hemorrhage After Endovascular Treatment of Acute Ischemic Stroke. Stroke 2017;48:1203–9.

[58] Lattanzi S, Cagnetti C, Provinciali L, et al. Neutrophil-to-Lymphocyte Ratio Predicts the Outcome of Acute Intracerebral Hemorrhage. Stroke 2016;47:1654–7.

[59] Świdorska M, Slomka A, Korbal P, et al. Association of Neutrophil-to-Lymphocyte Ratio and Lymphocyte-to-Monocyte Ratio with Treatment Modalities of Acute Ischaemic Stroke: A Pilot Study. Medicina (Kaunas) 2019;55:342.

[60] Lin C, Li N, Wang K, et al. Efficacy and safety of endovascular treatment versus intravenous thrombolysis for acute ischemic stroke: a meta-analysis of randomized controlled trials. PLOS One 2013;8:e77849.

[61] Singh R, Parsaik AK, Prokop LJ, et al. Endovascular therapy for acute ischemic stroke: a systematic review and meta-analysis. Mayo Clin Proc 2013;88:1056–65.

[62] Balsami JS, Sutherland BA, Edmunds LD, et al. A systematic review and meta-analysis of randomized controlled trials of endovascular thrombectomy compared with best medical treatment for acute ischemic stroke. Int J Stroke 2015;10:1168–78.

[63] Falk-Delgado A, Kuntze Soderqvist A, Fransen J, et al. Improved clinical outcome 3 months after endovascular treatment, including thrombectomy, in patients with acute ischaemic stroke: a meta-analysis. J Neurointerv Surg 2016;8:665–70.

[64] Hong KS, Ko SB, Lee JS, et al. Endovascular Recanalization Therapy in Acute Ischemic Stroke: Updated Meta-analysis of Randomized Controlled Trials. J Stroke 2015;17:269–81.

[65] Tan CC, Wang HF, Ji JL, et al. Endovascular Treatment Versus Intravenous Thrombolysis for Acute Ischemic Stroke: a Quantitative Review and Meta-Analysis of 21 Randomized Trials. Mol Neurobiol 2017;54:1369–78.

[66] Sheh KN, Terry JB, Nogueira RG, et al. Advanced modality imaging evaluation in acute ischemic stroke may lead to delayed endovascular reperfusion therapy without improvement in clinical outcomes. J Neurointerv Surg 2013;5:162–63.